half-life is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-07-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Reversed-phase high-performance liquid chromatography is widely used to assess purity and to separate the parent peptide from related substances. Mass spectrometry confirms identity and can resolve modifications that differ by a few daltons. Size-exclusion chromatography detects dimers and higher aggregates, which are relevant to both stability and immunogenicity questions. Peptide mapping with enzymatic digestion locates specific modifications along the sequence. Circular dichroism provides a secondary-structure profile, although it gives limited information about local conformational changes.
Quality control for peptide material focuses on identity, purity, content and the profile of impurities. Common degradants include deamidated and oxidised forms, plus aggregates formed during storage or handling. Forced degradation studies under heat, light, acid and peroxide help define which conditions accelerate change and which analytical methods detect it. Limits for individual impurities are set by pharmacopoeial monographs or manufacturer specifications. How much a given impurity affects biological activity is often uncertain, and conclusions may depend on the assay used.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Peptide backbone with a C18 fatty diacid side chain |
| Molecular weight | Approximately 4113 Da | Consistent with a 31-residue peptide plus linker |
| Appearance | White to off-white powder | Lyophilized solid; hygroscopic if left open |
| Solubility class | Sparingly soluble to soluble in water | Varies with pH and ionic strength |
| Typical analytical method | Reversed-phase HPLC with UV detection | Often paired with mass spectrometry for identity |
Certificate of analysis documents from suppliers typically report purity by chromatographic area, water content, and counter-ion identity. Independent verification is advisable because reported values can be generated under differing conditions. Impurity profiles matter for research use, where aggregates, deamidation products, and residual solvents may influence experimental results. Container, lot, and chain-of-custody records support traceability. Analytical results are method-dependent, so comparisons between laboratories require the same procedure and reference standards.
Lyophilized peptide material is typically stored at or below -20 °C, with -80 °C used for longer-term archives. Vials should remain sealed and desiccated because moisture promotes aggregation and hydrolysis. Repeated freeze-thaw cycles are avoided since they can alter peptide conformation and reduce recovery. Once reconstituted, solutions are generally kept at 2-8 °C and used within a defined window. Stability beyond those windows depends on buffer composition and concentration, and exact limits are product-specific rather than universal.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities by hydrophobicity. Mass spectrometry confirms molecular weight and detects truncation or modification products. Peptide mapping after enzymatic digestion verifies the amino acid sequence. Quantitation is often performed by LC-MS/MS or by immunoassay, and the two approaches can give different values because they measure different things. Method validation parameters such as accuracy, precision, and limit of quantitation are reported alongside results.
Handling guidance for research quantities calls for single-use aliquots, an inert atmosphere where practical, and avoidance of repeated freeze-thaw cycles that accelerate aggregation. Certificates of analysis typically report purity by peak area, water content, counter-ion identity, and residual solvent levels. In the scientific literature the compound is usually described by its full amino acid sequence, its registry number, or its structural class rather than by any proprietary label. Reporting standards vary between journals, and reviewers increasingly request raw chromatograms alongside tabulated purity figures. Whether current purity thresholds are adequate for every experimental context is debated.
Reversed-phase high-performance liquid chromatography with ultraviolet detection is the dominant approach for peptide purity assessment, usually paired with mass spectrometry to confirm molecular mass and sequence. Peptide mapping by enzymatic digestion and tandem mass spectrometry locates modifications such as deamidation and oxidation. Quantitation in plasma matrices can be performed by LC-MS/MS after solid-phase extraction. Method validation follows general guidance on accuracy, precision, linearity, and limits of detection. Comparability of results between laboratories, when no shared reference standard is available, remains an open question.
They further demonstrated that increased hepatic acetyl-CoA and glycerol flux—resulting from white adipose tissue inflammation—are key drivers of elevated gluconeogenesis in rodent models of type 2 diabetes (T2D). Based on the sn-1,2 DAG–nPKC hypothesis, Shulman's laboratory developed liver-targeted mitochondrial protonophores that reduce hepatic steatosis, insulin resistance, inflammation, and fibrosis in rodent and nonhuman primate models of MASLD and MASH. These compounds have advanced to clinical evaluation.
== Further reading == Hoffman, Maureane; Monroe, Dougald (2001). "A Cell-based Model of Hemostasis". Thrombosis and Haemostasis. 85 (6): 958–65. doi:10.1055/s-0037-1615947. PMID 11434702. Hoffman M, Monroe DM (February 2007). "Coagulation 2006: a modern view of hemostasis". Hematology/Oncology Clinics of North America. 21 (1): 1–11. doi:10.1016/j.hoc.2006.11.004. PMID 17258114.
Axonotmesis are a range of peripheral nerve injuries that are considered more severe than Neurapraxia and less severe than Neurotmesis. Axonotmesis involves loss of relative axon continuity and myelin covering, but preservation of the connective tissue framework (including encapsulating tissue, the epineurium and perineurium). Since connective tissue framework is preserved then axonal regeneration is possible, but recovery is slower. Other characteristics:
For the elimination of hazardous chemicals from the water, many treatment procedures have been applied. The processes involved in removing the contaminants include physical processes such as settling and filtration, chemical processes such as disinfection and coagulation, and biological processes such as slow sand filtration. A combination selected from the following processes (depending on the season and contaminants and chemicals present in the raw water) is used for municipal drinking water treatment worldwide.
Sources: en.wikipedia.org
== Effects and countermeasures == As nerve agents, the Novichok agents belong to the class of organophosphate acetylcholinesterase inhibitors. These chemical compounds inhibit the enzyme acetylcholinesterase, preventing the normal breakdown of the neurotransmitter acetylcholine. Acetylcholine concentrations then increase at neuromuscular junctions to cause involuntary contraction of all skeletal muscles (cholinergic crisis). This then leads to respiratory and cardiac arrest (as the victim's heart and diaphragm muscles no longer function normally) and finally death from heart failure or suffocation as copious fluid secretions fill the victim's lungs. As can be seen with other organophosphate poisonings, Novichok agents may cause lasting nerve damage, resulting in permanent disablement of victims, according to Russian scientists. Their effect on humans was demonstrated by the accidental exposure of Andrei Zheleznyakov, one of the scientists involved in their development, to the residue of an unspecified Novichok agent while working in a Moscow laboratory in May 1987. He was critically injured and took ten days to recover consciousness after the incident. He lost the ability to walk and was treated at a secret clinic in Leningrad for three months afterwards.
4-HO-DPT, also known as 4-hydroxy-N,N-dipropyltryptamine or as deprocin, is a psychedelic drug of the tryptamine and 4-hydroxytryptamine families related to psilocin (4-HO-DMT). It is taken orally. The drug acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT2A receptor. It produces psychedelic-like effects in animals. The drug is closely structurally related to other psychedelic tryptamines such as dipropyltryptamine (DPT), 5-MeO-DPT, and psilocin (4-HO-DMT), among others. 4-HO-DPT was first described in the scientific literature by David Repke and colleagues in 1977. It was encountered as a novel designer drug in 2012. A presumed prodrug, 4-AcO-DPT, is also known, and has likewise been encountered as a designer drug.
=== March === 11 March – Clive Revill, actor (The Empire Strikes Back, Irma La Douce, Oliver!) (born 1930). 13 March – Brian McMahon, venereologist, army officer, medical superintendent (Wakari Hospital, Dunedin Hospital) and lecturer (University of Otago) (born 1929). 14 March – Anne Nightingale, nurse, chair of the Nursing Council (1975–1984) (born 1932). 16 March – Gordon H. Brown, art historian, gallery director (Waikato Art Gallery, Sarjeant Gallery), and artist (born 1931). 20 March – Matt Mitchell, sailor (Team New Zealand, Alinghi, Oracle Team USA) (born c. 1971). 21 March – Nick Carter, lawyer and judge, Māori Land Court judge (1989–2002) (born 1935). 22 March – Alex Wyllie, rugby union player (Canterbury, national team) and coach (Canterbury, national team, Argentina) (born 1944). 31 March Sir Roger Clifford, 7th Baronet (born 1936). Ron Jones, obstetrician and gynaecologist (National Women's Hospital, University of Auckland), whistleblower in the "Unfortunate Experiment" (born 1939).
From Zunsser's view that "one cannot practice a profession like a trade" (p.157), he observed that, for instance, "an improvement in the mechanism of an automobile, or of a shoe buckle" — which were "matters of convenience or luxury", and therefore, "[could] be dispensed with easily by those who are forced to do without them" — were in an entirely "different category" from matters concerning "the relief of the sick and the prevention of unnecessary sorrow by the maintenance of individual and public health" which, "as soon as we are in possession of the knowledge of principles or methods which can contribute to these purposes their free utilization becomes a public necessity"; and, from this, he argued that "there is no valid argument in favor of the patenting of a useful method of preserving health, private or public, unless we admit [which Zinsser did not] that medical discoveries in no ethical sense differ from the purely commercial ones" (p.161). In addition to the question of whether it was ethical to patent medical inventions (pharmaceuticals, devices, apparatus, procedures, etc.), or not — in particular, whether "products of scientific research that affect public and individual health, particularly discoveries and inventions of a medical, pharmaceutical, therapeutic, or hygienic nature ...
=== LGBTQ+ rights === At the same time, her federal voting record included support for legislation protecting gender identity and expression under Canadian human rights and criminal law. In 2021, she stated that she opposed coercive conversion therapy. Still, she criticized Bill C-6 because its definition was, in her view, too broad and insufficiently precise. While campaigning for leadership of the Conservative Party of British Columbia, she promised to end provincial sexual orientation and gender identity inclusive (SOGI) education.
Sources: en.wikipedia.org
The difference in the COP of the blood and tissue tends to favor the reentry of fluid from the extravascular space, into the circulatory system. This tendency is opposed by the venous hydrostatic pressure, which tends to favor the exit of fluid from small vessels, into the interstitial space. The low protein theory for the pathogenesis of kwashiorkor held that a deficiency of serum proteins, caused by inadequate protein intake, disrupted this balance, and thus impaired the return flow of fluid from the interstitium into the capillary and venous structures. It has been taught that this is what accounts for the accumulation of extravascular fluid in kwashiorkor, and the subsequent pedal edema and abdominal distension. The low protein theory, which relies heavily upon Starling's theory for the movement of fluid in biological systems, provided a compelling rationale for the pathogenesis of edema in kwashiorkor. What it does not explain, however, is the entire array of disturbances that define the kwashiorkor syndrome. These include irritability, anorexia, skin desquamation, skin depigmentation, hair discoloration, reduced mitochondrial respiration, impaired lipid export from the liver without an accompanying reduction of lipoprotein synthesis, 'oxidative stress', glutathione depletions, transsulfuration disturbances, diffuse DNA hypomethylation, immune dysfunction, decreased transmethylation activity, and sulfated glycosaminoglycan deficiencies.
=== Societies and administration === The International Union of Basic and Clinical Pharmacology, Federation of European Pharmacological Societies, and European Association for Clinical Pharmacology and Therapeutics are organizations representing standardization and regulation of clinical and scientific pharmacology. Systems for medical classification of drugs with pharmaceutical codes have been developed. These include the National Drug Code (NDC), administered by Food and Drug Administration; Drug Identification Number (DIN), administered by Health Canada under the Food and Drugs Act; Hong Kong Drug Registration, administered by the Pharmaceutical Service of the Department of Health (Hong Kong), and National Pharmaceutical Product Index in South Africa. Hierarchical systems have also been developed, including the Anatomical Therapeutic Chemical Classification System (AT, or ATC/DDD), administered by World Health Organization; Generic Product Identifier, a hierarchical classification number published by MediSpan and SNOMED, C axis. Ingredients of drugs have been categorized by Unique Ingredient Identifiers.
The force is only dependent on the charge and electric field strength. The lighter ions will be deflected more and heavier ions less due to the difference in inertia and the ions will physically separate from each other in space into distinct beams of ions as they exit the electric sector. And the force on an ion in a linear homogenous magnetic field (a magnetic sector) is:
== Reduction of food packaging == Reduced packaging and sustainable packaging are becoming more frequent, although excessive overpackaging is still common. The motivations can be government regulations, consumer pressure, retailer pressure, and cost control. Reduced packaging often saves packaging costs. In the UK, a Local Government Association survey produced by the British Market Research Bureau compared a range of outlets to buy 29 common food items, and found that small, local retailers and market traders "produced less packaging and more that could be recycled than the larger supermarkets."
== Beginning of the war == On September 1, 1939, Hitler's Germany began its invasion of Poland, marking the beginning of World War II. On September 4, President Lázaro Cárdenas, faithful to Mexico's pacifist policy, declared neutrality in the European conflict, which was seen as a new kind of war. However, neutrality did not prevent the government from condemning aggression against the sovereignty of democratic nations. Mexico recognized the Polish government-in-exile, and in December 1939, it criticized the Soviet invasion of Finland. In 1940 and 1941, Mexico condemned the German invasions of Norway, the Netherlands, Belgium, Greece and Yugoslavia. Before the German aggression against Holland and Belgium, Cárdenas declared on May 13, 1940 that:
Sources: en.wikipedia.org
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.
Structural modifications, including a fatty acid side chain and non-natural amino acid substitutions, slow enzymatic breakdown and promote albumin binding. These changes support once-weekly dosing rather than twice-daily administration.
The pathways involving insulin, glucagon, gastric emptying, and appetite signaling are well described. How much each pathway contributes to weight reduction in a given person is not fully established.
Lower temperatures slow hydrolysis, oxidation and aggregation reactions that degrade the molecule over time. Lyophilised powder is more tolerant than solution, but both benefit from controlled conditions.